Clinical Trial Update: Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1b study is evaluating talquetamab bridging therapy followed by cilta-cel in relapsed/refractory multiple myeloma; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carvykti (ciltacabtagene autoleucel)
• Talquetamab (talquetamab)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING